306 related items for PubMed ID: 29959373
1. The role of B7-1 in proteinuria of glomerular origin.
Novelli R, Benigni A, Remuzzi G.
Nat Rev Nephrol; 2018 Sep; 14(9):589-596. PubMed ID: 29959373
[Abstract] [Full Text] [Related]
2. Podocyte-Targeted Treatment for Proteinuric Kidney Disease.
Mundel P.
Semin Nephrol; 2016 Nov; 36(6):459-462. PubMed ID: 27987545
[No Abstract] [Full Text] [Related]
3. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G.
Am J Physiol Renal Physiol; 2016 Mar 01; 310(5):F335-41. PubMed ID: 26697986
[Abstract] [Full Text] [Related]
4. CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.
Teh YM, Lim SK, Jusoh N, Osman K, Mualif SA.
Biomed Res Int; 2021 Mar 01; 2021():6671552. PubMed ID: 33506028
[Abstract] [Full Text] [Related]
5. Abatacept in B7-1-positive proteinuric kidney disease.
Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW, Mundel P.
N Engl J Med; 2013 Dec 19; 369(25):2416-23. PubMed ID: 24206430
[Abstract] [Full Text] [Related]
6. Minimal change nephropathy and focal segmental glomerulosclerosis.
Mathieson PW.
Semin Immunopathol; 2007 Nov 19; 29(4):415-26. PubMed ID: 17955243
[Abstract] [Full Text] [Related]
7. Podocyte Expression of B7-1/CD80: Is it a Reliable Biomarker for the Treatment of Proteinuric Kidney Diseases with Abatacept?
Salant DJ.
J Am Soc Nephrol; 2016 Apr 19; 27(4):963-5. PubMed ID: 26400567
[No Abstract] [Full Text] [Related]
8. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
Cara-Fuentes G, Venkatareddy M, Verma R, Segarra A, Cleuren AC, Martínez-Ramos A, Johnson RJ, Garg P.
Pediatr Nephrol; 2020 Oct 19; 35(10):1887-1896. PubMed ID: 32399663
[Abstract] [Full Text] [Related]
9. Roles of microRNAs in renal disorders related to primary podocyte dysfunction.
Iranzad R, Motavalli R, Ghassabi A, Pourakbari R, Etemadi J, Yousefi M.
Life Sci; 2021 Jul 15; 277():119463. PubMed ID: 33862110
[Abstract] [Full Text] [Related]
10. The costimulatory receptor B7-1 is not induced in injured podocytes.
Baye E, Gallazzini M, Delville M, Legendre C, Terzi F, Canaud G.
Kidney Int; 2016 Nov 15; 90(5):1037-1044. PubMed ID: 27528551
[Abstract] [Full Text] [Related]
11. Urinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease.
Ahmed HM, Ezzat DA, Doudar NA, Adel M.
Iran J Kidney Dis; 2018 Mar 15; 12(2):107-111. PubMed ID: 29507273
[Abstract] [Full Text] [Related]
12. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS.
Delville M, Baye E, Durrbach A, Audard V, Kofman T, Braun L, Olagne J, Nguyen C, Deschênes G, Moulin B, Delahousse M, Kesler-Roussey G, Beaudreuil S, Martinez F, Rabant M, Grimbert P, Gallazzini M, Terzi F, Legendre C, Canaud G.
J Am Soc Nephrol; 2016 Aug 15; 27(8):2520-7. PubMed ID: 26701979
[Abstract] [Full Text] [Related]
13. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
Eriguchi M, Yotsueda R, Torisu K, Kawai Y, Hasegawa S, Tanaka S, Noguchi H, Masutani K, Kitazono T, Tsuruya K.
Am J Physiol Renal Physiol; 2016 Feb 15; 310(4):F322-33. PubMed ID: 26632605
[Abstract] [Full Text] [Related]
14. Morphologic Analysis of Urinary Podocytes in Focal Segmental Glomerulosclerosis.
Shirai Y, Miura K, Yokoyama T, Horita S, Nakayama H, Seino H, Ando T, Shiratori A, Yabuuchi T, Kaneko N, Ishiwa S, Ishizuka K, Hara M, Hattori M.
Kidney360; 2021 Mar 25; 2(3):477-486. PubMed ID: 35369007
[Abstract] [Full Text] [Related]
15. Urinary CD80: a biomarker for a favorable response to corticosteroids in minimal change disease.
Cara-Fuentes G, Lanaspa MA, Garcia GE, Banks M, Garin EH, Johnson RJ.
Pediatr Nephrol; 2018 Jul 25; 33(7):1101-1103. PubMed ID: 29492674
[Abstract] [Full Text] [Related]
16. Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.
Herrera M, Söderberg M, Sabirsh A, Valastro B, Mölne J, Santamaria B, Valverde AM, Guionaud S, Heasman S, Bigley A, Jermutus L, Rondinone C, Coghlan M, Baker D, Quinn CM.
Am J Physiol Renal Physiol; 2017 Apr 01; 312(4):F748-F759. PubMed ID: 27440778
[Abstract] [Full Text] [Related]
17. CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood.
Eroglu FK, Orhan D, İnözü M, Duzova A, Gulhan B, Ozaltin F, Topaloglu R.
Pediatr Int; 2019 Dec 01; 61(12):1250-1256. PubMed ID: 31513327
[Abstract] [Full Text] [Related]
18. Inhibition of the glucocorticoid receptor attenuates proteinuric kidney diseases in multiple species.
Stamellou E, Agrawal S, Siegerist F, Buse M, Kuppe C, Lange T, Buhl EM, Alam J, Strieder T, Boor P, Ostendorf T, Gröne HJ, Floege J, Smoyer WE, Endlich N, Moeller MJ.
Nephrol Dial Transplant; 2024 Jun 28; 39(7):1181-1193. PubMed ID: 38037533
[Abstract] [Full Text] [Related]
19. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.
Hansrivijit P, Puthenpura MM, Ghahramani N.
Clin Nephrol; 2020 Sep 28; 94(3):117-126. PubMed ID: 32589135
[Abstract] [Full Text] [Related]
20. Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases.
Manabe S, Nitta K, Nagata M.
Contrib Nephrol; 2018 Sep 28; 195():131-142. PubMed ID: 29734158
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
